Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease.

Abstract

Biomarkers to guide clinical decision making at diagnosis of inflammatory bowel disease [IBD] are urgently needed. We investigated a composite serum N-glycomic biomarker to predict future disease course in a discovery cohort of 244 newly diagnosed IBD patients. In all, 47 individual glycan peaks were analysed using ultra-high performance liquid chromatography, identifying 105 glycoforms from which 24 derived glycan traits were calculated. Multivariable logistic regression was performed to determine associations of derived glycan traits with disease. Cox proportional hazard models were used to predict treatment escalation from first-line treatment to biologics or surgery (hazard ratio [HR] 25.9, p = 1.1 × 10-12; 95% confidence interval [CI], 8.52-78.78). Application to an independent replication cohort of 54 IBD patients yielded an HR of 5.1 [p = 1.1 × 10-5; 95% CI, 2.54-10.1]. These data demonstrate the prognostic capacity of serum N-glycan biomarkers and represent a step towards personalised medicine in IBD.

• Authors: Archana Shubhakar, Bas C Jansen, Alex T Adams, Karli R Reiding, Nicholas T Ventham, Rahul Kalla, Daniel Bergemalm, Paulina A Urbanowicz, Richard A Gardner, IBD-BIOM Consortium, Manfred Wuhrer, Jonas Halfvarson, Jack Satsangi, Daryl L Fernandes, Daniel I R Spencer
• Journal: Journal of Crohn's & colitis (J Crohns Colitis) Vol. 17 Issue 6 Pg. 919-932 (Jun 16 2023) ISSN: 1876-4479 [Electronic] England
• PMID: 36694402 (Publication Type: Journal Article)
• Copyright: © The Author(s) 2023. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: [email protected].

Chemical References

• Biomarkers
• Polysaccharides

Topics

• Humans
• Colitis, Ulcerative (diagnosis)
• Crohn Disease (complications)
• Glycomics
• Inflammatory Bowel Diseases (complications)
• Biomarkers
• Polysaccharides